2H-色烯-3-甲醇 | 115822-61-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: 2H-色烯-3-甲醇
• 英文名称: (2H-chromen-3-yl)methanol
• 英文别名: 2H-chromen-3-ylmethanol
• CAS: 115822-61-2
• 化学式: C₁₀H₁₀O₂
• mdl: MFCD03659707
• 分子量: 162.188
• InChiKey: UCIFNZYYNUQDAW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险类别码：
  R36/37/38
• 安全说明：
  S26,S36/37/39

SDS

Name:	2H-chromen-3-ylmethanol 90+% Material Safety Data Sheet
Synonym:
CAS:	115822-61-2

Section 1 - Chemical Product MSDS Name:2H-chromen-3-ylmethanol 90+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
115822-61-2	2H-Chromen-3-ylmethanol	90+%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Store under nitrogen.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 115822-61-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Oil
Color: brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H10O2
Molecular Weight: 162.19

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, acid chlorides, acids, halogenated agents, halogens.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Not available.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 115822-61-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2H-Chromen-3-ylmethanol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 115822-61-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 115822-61-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 115822-61-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2H-色烯-3-甲醇 在 氯化亚砜 作用下， 以 四氢呋喃 、 氯仿 为溶剂， 反应 82.0h， 生成 1-(3-Chromenylmethyl)piperidine
  参考文献：
  名称：

  Pharmacomodulation d'adrénolytiques aα en série benzopyrannique

  摘要：

  DOI：

  10.1016/0223-5234(87)90294-7
• 作为产物：
  描述：

  2H-苯并吡喃-3-甲酸 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 4.0h， 以71%的产率得到2H-色烯-3-甲醇
  参考文献：
  名称：

  Pharmacomodulation d'adrénolytiques aα en série benzopyrannique

  摘要：

  DOI：

  10.1016/0223-5234(87)90294-7

文献信息

• [EN] TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS<br/>[FR] TRAITEMENT OU PROPHYLAXIE D'ÉTATS PROLIFÉRATIFS
  申请人：UNIV DUNDEE

  公开号：WO2010125350A1

  公开（公告）日：2010-11-04

  The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.

  该发明涉及用于治疗或预防癌症和其他增殖性疾病的新化合物，例如这些疾病的特征是细胞表达细胞色素P450 1B1（CYP1B1）及其等位基因变体。该发明还提供包含一种或多种此类化合物的药物组合物，用于医学治疗，例如用于治疗或预防癌症或其他增殖性疾病，以及用于治疗人类或非人类动物患者的癌症或其他疾病的方法。该发明还提供用于识别用于治疗或预防癌症和其他增殖性疾病的新化合物的方法，例如这些疾病的特征是细胞表达CYP1B1及其等位基因变体。该发明还提供一种用于确定该发明中化合物治疗癌症的疗效的方法。
• Dianionic Phase-Transfer Catalyst for Asymmetric Fluoro-cyclization
  作者：Hiromichi Egami、Tomoki Niwa、Hitomi Sato、Ryo Hotta、Daiki Rouno、Yuji Kawato、Yoshitaka Hamashima

  DOI：10.1021/jacs.7b13690

  日期：2018.2.28

  dicationic nature of the electrophilic fluorinating reagent, Selectfluor (1), we rationally designed a series of dicarboxylic acid precatalysts (2), which, when deprotonated, act as anionic phase-transfer catalysts for asymmetric fluorination of alkenes. Among them, 2a having the shortest linker moiety efficiently catalyzed unprecedented 6-endo-fluoro-cyclization of various allylic amides, affording

  受亲电氟化试剂 Selectfluor (1) 的双阳离子性质的启发，我们合理设计了一系列二羧酸预催化剂 (2)，当去质子化时，它们作为阴离子相转移催化剂用于烯烃的不对称氟化。其中，具有最短连接体部分的 2a 有效地催化了各种烯丙基酰胺的前所未有的 6-内氟环化，得到了具有高对映选择性（高达 99% ee）的氟化二氢恶嗪化合物。除环状底物外，无环三取代烯烃以良好的非对映选择性进行反应，而线性二取代烯烃的非对映选择性较低。结果表明反应通过氟碳正离子中间体进行。
• MONOAMINE RE-UPTAKE INHIBITORS AND METHODS RELATING THERETO
  申请人：Pontillo Joseph

  公开号：US20060276454A1

  公开（公告）日：2006-12-07

  Monoamine re-uptake inhibitors and more specifically serotonin and noradrenaline re-uptake inhibitors are disclosed that have utility in the treatment of disorders of the central or peripheral nervous system in both men and women. The compounds of this invention have the structure: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , m, n, W, X, Y, and Z are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts, esters and solvates thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting monoamine re-uptake in a subject in need thereof.

  单胺再摄取抑制剂，更具体地说是血清素和去甲肾上腺素再摄取抑制剂，被披露具有在男性和女性中治疗中枢或外周神经系统疾病的效用。本发明的化合物具有以下结构： 其中R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，R 6 ，m，n，W，X，Y和Z如本文所定义，包括立体异构体，前药和药学上可接受的盐，酯和溶剂。还披露了含有本发明化合物的组合物与药学上可接受的载体，以及与使用该化合物抑制受需要的主体中的单胺再摄取有关的方法。
• Synthesis of Robalzotan, Ebalzotan, and Rotigotine Precursors via the Stereoselective Multienzymatic Cascade Reduction of α,β-Unsaturated Aldehydes
  作者：Elisabetta Brenna、Francesco G. Gatti、Luciana Malpezzi、Daniela Monti、Fabio Parmeggiani、Alessandro Sacchetti

  DOI：10.1021/jo4003097

  日期：2013.5.17

  The key step is based on a multienzymatic reduction of an α,β-unsaturated aldehyde or ketone to give the saturated primary or secondary alcohol, in a high yield and with a high ee. The catalytic system consists of the combination of an ene-reductase (ER; i.e., OYE2 or OYE3 belonging to the Old Yellow Enzyme family) with an alcohol dehydrogenase (ADH), applying the in situ substrate feeding product removal

  据报道，基于四氢化萘或苯并二氢吡喃结构部分的立体选择性合成双环伯胺或仲胺。这些胺是重要的活性药物成分（如罗替戈汀（Neupro），罗巴唑坦和依巴唑坦）的前体。关键步骤是基于α，β-不饱和醛或酮的多酶还原，以高收率和高ee值得到饱和伯醇或仲醇。催化系统由烯还原酶（ER；即属于Old Yellow Enzyme家族的OYE2或OYE3）与醇脱氢酶（ADH）结合而成，采用原位底物进料产品去除技术。通过该系统，烯丙基醇副产物的形成和手性不稳定的α-取代的醛中间体的外消旋化被最小化。通过库尔修斯重排精制伯醇。OYE2与Prelog或抗Prelog ADH的组合可以制备ee> 99％和de> 87％的仲醇。通过与真实样品进行比较，明确确定了伯胺的绝对构型。通过X射线晶体结构和Mosher酯的NMR分析确定仲醇的立体化学。
• Iridium‐Catalyzed Enantioselective Hydrogenation of Indole and Benzofuran Derivatives
  作者：Yao Ge、Zheng Wang、Zhaobin Han、Kuiling Ding

  DOI：10.1002/chem.202002532

  日期：2020.12

  Enantioselective hydrogenation of a broad spectrum of N‐, O‐, and S‐containing aromatic benzoheterocycles or nonaromatic unsaturated heterocycles has been realized by using an Ir/SpinPHOX (SpinPHOX=spiro[4,4]‐1,6‐nonadiene‐based phosphine‐oxazoline) complex as the catalyst, affording an array of the corresponding chiral benzoheterocycles (30 examples) with excellent enantioselectivities (>99 % ee in

  通过使用Ir / SpinPHOX（SpinPHOX = spiro [4,4] -1,6-壬二烯基膦，已经实现了对N，O和S的各种芳族苯并杂环或非芳族不饱和杂环的对映选择性氢化） -恶唑啉）络合物作为催化剂，可提供一系列相应的手性苯并杂环化合物（30个实例），具有出色的对映选择性（大多数情况下> 99％  ee），周转数高达500。